These findings suggested that STAT5B could be a potential and effective target in managing PCa after resistance to hormonal therapy, and the role of other upstream pathways in STAT5 activation and progression of prostate cancer needs further exploration. The gene discussed is STAT5A; the disease is posterior cortical atrophy.